Key Takeaways
- • The University of Toronto, McMaster University and Venture Ontario have joined Genesys Capital to create the Genesys University Seed Fund, an early-stage life sciences venture capital fund.
- • The fund has held a first close representing over $30 million of commitments, with backers including U of T, McMaster, the Temerty Group, Venture Ontario and RBC, and is seeking additional capital to reach up to $40 million.
- • Genesys Capital will oversee and manage the fund; the firm reports more than $400 million invested over 25 years and 20 exits as a founding investor.
- • The fund targets a funding gap that, per the announcement, pushes Ontario life sciences innovators to relocate to Boston and Silicon Valley.
Summary
The University of Toronto (U of T), McMaster University and Venture Ontario announced they are partnering with veteran investor Genesys Capital to create the Genesys University Seed Fund, a new early-stage life sciences venture capital vehicle, according to a Business Wire release dated July 8, 2026. The fund is intended to translate university-based commercial ideas into viable companies addressing health challenges. To date it has received support from the Temerty Group, Venture Ontario, RBC, U of T and McMaster, and has held a first close representing over $30 million of commitments. It is currently accepting further investment from private and public sector investors to increase its size to up to $40 million.
The announcement frames the initiative as a response to a capital gap. Per the release, Ontario has nearly 76,000 skilled life sciences workers across more than 2,000 firms, one of the largest clusters in North America, yet it trails U.S. jurisdictions in access to early-stage investment, prompting many innovators to relocate to Boston and Silicon Valley. U of T and McMaster said they are following models at MIT, the University of Pennsylvania, UC Berkeley and Harvard.
Genesys Capital will manage the fund. The firm says it has invested more than $400 million over 25 years in biotechnology, pharmaceuticals and medical technology companies. As limited partners, U of T and McMaster will direct their returns to further research and innovation at the two universities. U of T reports more than 1,500 venture-backed startups over the past five years that have raised over $14 billion, and McMaster reports nearly 400 supported startups, including Fusion Pharmaceuticals, which AstraZeneca acquired in 2024 for $2 billion USD.
Ontario government officials, including Economic Development Minister Vic Fedeli and Colleges, Universities, Research Excellence and Security Minister Nolan Quinn, endorsed the initiative, which Venture Ontario CEO Steve Romanyshyn said will help anchor early-stage life sciences investment in the province.
The announcement frames the initiative as a response to a capital gap. Per the release, Ontario has nearly 76,000 skilled life sciences workers across more than 2,000 firms, one of the largest clusters in North America, yet it trails U.S. jurisdictions in access to early-stage investment, prompting many innovators to relocate to Boston and Silicon Valley. U of T and McMaster said they are following models at MIT, the University of Pennsylvania, UC Berkeley and Harvard.
Genesys Capital will manage the fund. The firm says it has invested more than $400 million over 25 years in biotechnology, pharmaceuticals and medical technology companies. As limited partners, U of T and McMaster will direct their returns to further research and innovation at the two universities. U of T reports more than 1,500 venture-backed startups over the past five years that have raised over $14 billion, and McMaster reports nearly 400 supported startups, including Fusion Pharmaceuticals, which AstraZeneca acquired in 2024 for $2 billion USD.
Ontario government officials, including Economic Development Minister Vic Fedeli and Colleges, Universities, Research Excellence and Security Minister Nolan Quinn, endorsed the initiative, which Venture Ontario CEO Steve Romanyshyn said will help anchor early-stage life sciences investment in the province.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.